{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T13:48:35Z","timestamp":1766065715007,"version":"3.48.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008408","name":"Kristianstad University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008408","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fetal bovine serum (FBS) is widely used as a growth supplement in cell culture due to its richness in embryonic growth-promoting factors, but presents ethical concerns, batch-to-batch variability, high cost, and biosafety issues. Alternative supplements are needed to support consistent and reliable cell growth in vitro. Human platelet lysate (hPL) and chemically defined supplements offer potential substitutes, but they require evaluation across different cell types. This study aimed to evaluate the effectiveness of two commercial serum supplements, PLTGold (an hPL product) and FastGro (a chemically defined supplement), as alternatives to FBS for supporting the growth and proliferation of the prostate cancer cell lines PC-3 and LNCaP. These cell lines were cultured in media supplemented with different concentrations of FBS, PLTGold, or FastGro. Cell viability was assessed using the MTT assay after 3, 4, and 7 days. Cell cycle distribution was analyzed using propidium iodide staining and flow cytometry after 3 days of culture. Finally, BrdU incorporation assays were conducted to evaluate cell proliferation. Interestingly, PLTGold demonstrated cell viability comparable to or even greater than FBS in PC-3 cells and maintained LNCaP viability, whereas FastGro reduced the viability in both cell lines. FastGro-induced cell cycle arrest was observed in PC-3 cells, indicating a more pronounced inhibitory effect. PLTGold is a promising alternative to FBS, particularly for PC-3 cells, whereas FastGro requires optimization. These results suggest that serum supplements can be used as substitutes for FBS, but further optimization and validation are required.<\/jats:p>","DOI":"10.1007\/s11033-025-11362-w","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T13:43:48Z","timestamp":1766065428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of prostate cancer cell line growth in fetal bovine serum and animal free supplements"],"prefix":"10.1007","volume":"53","author":[{"given":"Emma","family":"Itting","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anette Gj\u00f6rloff","family":"Wingren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Tassidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"6","key":"11362_CR1","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1084\/jem.108.6.945","volume":"108","author":"TT Puck","year":"1958","unstructured":"Puck TT, Cieciura SJ, Robinson A (1958) Genetics of somatic mammalian cells. III. Long-term cultivation of euploid cells from human and animal subjects. J Exp Med 108(6):945\u2013956. https:\/\/doi.org\/10.1084\/jem.108.6.945","journal-title":"J Exp Med"},{"issue":"1","key":"11362_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tiv.2003.08.009","volume":"18","author":"J van der Valk","year":"2004","unstructured":"van der Valk J et al (2004) The humane collection of fetal bovine serum and possibilities for serum-free cell and tissue culture. Toxicol In Vitro 18(1):1\u201312. https:\/\/doi.org\/10.1016\/j.tiv.2003.08.009","journal-title":"Toxicol In Vitro"},{"issue":"4","key":"11362_CR3","first-page":"275","volume":"20","author":"G Gstraunthaler","year":"2003","unstructured":"Gstraunthaler G (2003) Alternatives to the use of fetal bovine serum: serum-free cell culture. ALTEX 20(4):275\u2013281","journal-title":"ALTEX"},{"issue":"5","key":"11362_CR4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s10616-013-9633-8","volume":"65","author":"G Gstraunthaler","year":"2013","unstructured":"Gstraunthaler G, Lindl T, van der Valk J (2013) A plea to reduce or replace fetal bovine serum in cell culture media. Cytotechnology 65(5):791\u2013793. https:\/\/doi.org\/10.1007\/s10616-013-9633-8","journal-title":"Cytotechnology"},{"issue":"15","key":"11362_CR5","doi-asserted-by":"publisher","first-page":"e2004182","DOI":"10.1002\/smll.202004182","volume":"17","author":"F Fontana","year":"2021","unstructured":"Fontana F et al (2021) Requirements for animal experiments: problems and challenges. Small 17(15):e2004182. https:\/\/doi.org\/10.1002\/smll.202004182","journal-title":"Small"},{"issue":"6","key":"11362_CR6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/BF02619594","volume":"19","author":"SN Mohamed","year":"1983","unstructured":"Mohamed SN, Holmes R, Hartzell CR (1983) A serum-free, chemically-defined medium for function and growth of primary neonatal rat heart cell cultures. Vitro 19(6):471\u2013478. https:\/\/doi.org\/10.1007\/BF02619594","journal-title":"Vitro"},{"issue":"5\u20136","key":"11362_CR7","first-page":"427","volume":"1","author":"L Afjehi-Sadat","year":"2004","unstructured":"Afjehi-Sadat L et al (2004) Proteomic profiling of signaling proteins in ten different tumor cell lines. Cancer Genomics Proteom 1(5\u20136):427\u2013454","journal-title":"Cancer Genomics Proteom"},{"issue":"2","key":"11362_CR8","doi-asserted-by":"publisher","first-page":"e31532","DOI":"10.1371\/journal.pone.0031532","volume":"7","author":"JA Aka","year":"2012","unstructured":"Aka JA, Lin SX (2012) Comparison of functional proteomic analyses of human breast cancer cell lines T47D and MCF7. PLoS One 7(2):e31532. https:\/\/doi.org\/10.1371\/journal.pone.0031532","journal-title":"PLoS One"},{"key":"11362_CR9","doi-asserted-by":"publisher","first-page":"964397","DOI":"10.3389\/fbioe.2022.964397","volume":"10","author":"M Jang","year":"2022","unstructured":"Jang M, Pete ES, Bruheim P (2022) The impact of serum-free culture on HEK293 cells: from the establishment of suspension and adherent serum-free adaptation cultures to the investigation of growth and metabolic profiles. Front Bioeng Biotechnol 10:964397. https:\/\/doi.org\/10.3389\/fbioe.2022.964397","journal-title":"Front Bioeng Biotechnol"},{"issue":"3","key":"11362_CR10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1242\/jcs.94.3.567","volume":"94","author":"Y Umeno","year":"1989","unstructured":"Umeno Y, Okuda A, Kimura G (1989) Proliferative behaviour of fibroblasts in plasma-rich culture medium. J Cell Sci 94(3):567\u201375. https:\/\/doi.org\/10.1242\/jcs.94.3.567","journal-title":"J Cell Sci"},{"key":"11362_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.biomaterials.2015.10.065","volume":"76","author":"T Burnouf","year":"2016","unstructured":"Burnouf T et al (2016) Human platelet lysate: replacing fetal bovine serum as a gold standard for human cell propagation? Biomaterials 76:371\u2013387. https:\/\/doi.org\/10.1016\/j.biomaterials.2015.10.065","journal-title":"Biomaterials"},{"issue":"1","key":"11362_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00441-012-1360-5","volume":"348","author":"BA Naaijkens","year":"2012","unstructured":"Naaijkens BA et al (2012) Human platelet lysate as a fetal bovine serum substitute improves human adipose-derived stromal cell culture for future cardiac repair applications. Cell Tissue Res 348(1):119\u2013130. https:\/\/doi.org\/10.1007\/s00441-012-1360-5","journal-title":"Cell Tissue Res"},{"issue":"4","key":"11362_CR13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.14573\/altex.2011.4.305","volume":"28","author":"C Rauch","year":"2011","unstructured":"Rauch C et al (2011) Alternatives to the use of fetal bovine serum: human platelet lysates as a serum substitute in cell culture media. Altex 28(4):305\u2013316. https:\/\/doi.org\/10.14573\/altex.2011.4.305","journal-title":"Altex"},{"key":"11362_CR14","doi-asserted-by":"publisher","first-page":"102592","DOI":"10.1016\/j.mex.2024.102592","volume":"12","author":"T Weber","year":"2024","unstructured":"Weber T, Bajramovic J, Oredsson S (2024) Preparation of a universally usable, animal product free, defined medium for 2D and 3D culturing of normal and cancer cells. MethodsX 12:102592. https:\/\/doi.org\/10.1016\/j.mex.2024.102592","journal-title":"MethodsX"},{"issue":"4","key":"11362_CR15","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s12010-012-0068-z","volume":"169","author":"ME Rodrigues","year":"2013","unstructured":"Rodrigues ME et al (2013) Advances and drawbacks of the adaptation to serum-free culture of CHO-K1 cells for monoclonal antibody production. Appl Biochem Biotechnol 169(4):1279\u20131291. https:\/\/doi.org\/10.1007\/s12010-012-0068-z","journal-title":"Appl Biochem Biotechnol"},{"key":"11362_CR16","doi-asserted-by":"publisher","DOI":"10.14440\/jbm.2015.63","author":"D Cunningham","year":"2015","unstructured":"Cunningham D, You Z (2015) In vitro and in vivo model systems used in prostate cancer research. J Biol Methods. https:\/\/doi.org\/10.14440\/jbm.2015.63","journal-title":"J Biol Methods"},{"key":"11362_CR17","first-page":"115","volume":"37","author":"JS Horoszewicz","year":"1980","unstructured":"Horoszewicz JS et al (1980) The LNCaP cell line\u2013a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 37:115\u2013132","journal-title":"Prog Clin Biol Res"},{"issue":"4","key":"11362_CR18","first-page":"1809","volume":"43","author":"JS Horoszewicz","year":"1983","unstructured":"Horoszewicz JS et al (1983) LNCaP model of human prostatic carcinoma. Cancer Res 43(4):1809\u20131818","journal-title":"Cancer Res"},{"issue":"1","key":"11362_CR19","first-page":"16","volume":"17","author":"ME Kaighn","year":"1979","unstructured":"Kaighn ME et al (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17(1):16\u201323","journal-title":"Invest Urol"},{"issue":"2","key":"11362_CR20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/01.ju.0000141580.30910.57","volume":"173","author":"RE Sobel","year":"2005","unstructured":"Sobel RE, Sadar MD (2005) Cell lines used in prostate cancer research: a compendium of old and new lines\u2013part 1. J Urol 173(2):342\u2013359. https:\/\/doi.org\/10.1097\/01.ju.0000141580.30910.57","journal-title":"J Urol"},{"issue":"10","key":"11362_CR21","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/pros.20960","volume":"69","author":"MG Dozmorov","year":"2009","unstructured":"Dozmorov MG et al (2009) Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells. Prostate 69(10):1077\u201390. https:\/\/doi.org\/10.1002\/pros.20960","journal-title":"Prostate"},{"issue":"3","key":"11362_CR22","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41391-023-00679-x","volume":"26","author":"L Moya","year":"2023","unstructured":"Moya L et al (2023) Characterisation of cell lines derived from prostate cancer patients with localised disease. Prostate Cancer Prostatic Dis 26(3):614\u2013624. https:\/\/doi.org\/10.1038\/s41391-023-00679-x","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"11362_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s12038-011-9170-6","volume":"37","author":"S Mahoney","year":"2012","unstructured":"Mahoney S et al (2012) Cytotoxic effects of the novel isoflavone, phenoxodiol, on prostate cancer cell lines. J Biosci 37(1):73\u201384. https:\/\/doi.org\/10.1007\/s12038-011-9170-6","journal-title":"J Biosci"},{"issue":"13","key":"11362_CR24","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/pros.20991","volume":"69","author":"C Sanchez","year":"2009","unstructured":"Sanchez C et al (2009) Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. Prostate 69(13):1448\u201359. https:\/\/doi.org\/10.1002\/pros.20991","journal-title":"Prostate"},{"issue":"1","key":"11362_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.14573\/altex.1705101","volume":"35","author":"J van der Valk","year":"2018","unstructured":"van der Valk J et al (2018) Fetal bovine serum (FBS): past - present - future. ALTEX 35(1):99\u2013118. https:\/\/doi.org\/10.14573\/altex.1705101","journal-title":"ALTEX"},{"issue":"6","key":"11362_CR26","doi-asserted-by":"publisher","first-page":"e0178960","DOI":"10.1371\/journal.pone.0178960","volume":"12","author":"CY Fang","year":"2017","unstructured":"Fang CY et al (2017) Long-term growth comparison studies of FBS and FBS alternatives in six head and neck cell lines. PLoS One 12(6):e0178960. https:\/\/doi.org\/10.1371\/journal.pone.0178960","journal-title":"PLoS One"},{"issue":"2","key":"11362_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/rmb2.12024","volume":"16","author":"T Yao","year":"2017","unstructured":"Yao T, Asayama Y (2017) Animal-cell culture media: history, characteristics, and current issues. Reprod Med Biol 16(2):99\u2013117. https:\/\/doi.org\/10.1002\/rmb2.12024","journal-title":"Reprod Med Biol"},{"issue":"2","key":"11362_CR28","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/09537104.2020.1849602","volume":"32","author":"L Barro","year":"2021","unstructured":"Barro L et al (2021) Human platelet lysates for human cell propagation. Platelets 32(2):152\u2013162. https:\/\/doi.org\/10.1080\/09537104.2020.1849602","journal-title":"Platelets"},{"issue":"8","key":"11362_CR29","doi-asserted-by":"publisher","first-page":"e07686","DOI":"10.1016\/j.heliyon.2021.e07686","volume":"7","author":"K Subbiahanadar Chelladurai","year":"2021","unstructured":"Subbiahanadar Chelladurai K et al (2021) Alternative to FBS in animal cell culture - an overview and future perspective. Heliyon 7(8):e07686. https:\/\/doi.org\/10.1016\/j.heliyon.2021.e07686","journal-title":"Heliyon"},{"issue":"6","key":"11362_CR30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1159\/000356236","volume":"40","author":"K Witzeneder","year":"2013","unstructured":"Witzeneder K et al (2013) Human-derived alternatives to fetal bovine serum in cell culture. Transfus Med Hemother 40(6):417\u2013423. https:\/\/doi.org\/10.1159\/000356236","journal-title":"Transfus Med Hemother"},{"issue":"8","key":"11362_CR31","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/j.1537-2995.2007.01220.x","volume":"47","author":"K Schallmoser","year":"2007","unstructured":"Schallmoser K et al (2007) Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion 47(8):1436\u201346. https:\/\/doi.org\/10.1111\/j.1537-2995.2007.01220.x","journal-title":"Transfusion"},{"issue":"1","key":"11362_CR32","doi-asserted-by":"publisher","first-page":"12233","DOI":"10.1038\/s41598-021-91500-z","volume":"11","author":"L de Finkel","year":"2021","unstructured":"de Finkel L (2021) Serum free culture for the expansion and study of type 2 innate lymphoid cells. Sci Rep 11(1):12233. https:\/\/doi.org\/10.1038\/s41598-021-91500-z","journal-title":"Sci Rep"},{"issue":"1","key":"11362_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.30714\/j-ebr.2022.164","volume":"6","author":"B Hernroth","year":"2023","unstructured":"Hernroth B, Tassidis H (2023) Viability effects on cell cycle synchronization of different prostate cancer cell lines: a brief report. EXPERIMENTAL BIOMEDICAL Res 6(1):1\u20135. https:\/\/doi.org\/10.30714\/j-ebr.2022.164","journal-title":"EXPERIMENTAL BIOMEDICAL Res"},{"issue":"9","key":"11362_CR34","doi-asserted-by":"publisher","first-page":"e0185470","DOI":"10.1371\/journal.pone.0185470","volume":"12","author":"A Zhao","year":"2017","unstructured":"Zhao A et al (2017) Use of real-time cellular analysis and Plackett-Burman design to develop the serum-free media for PC-3 prostate cancer cells. PLoS One 12(9):e0185470. https:\/\/doi.org\/10.1371\/journal.pone.0185470","journal-title":"PLoS One"},{"key":"11362_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcot.2021.101534","volume":"21","author":"L da Fonseca","year":"2021","unstructured":"da Fonseca L et al (2021) Human platelet lysate - a potent (and overlooked) orthobiologic. J Clin Orthop Trauma 21:101534. https:\/\/doi.org\/10.1016\/j.jcot.2021.101534","journal-title":"J Clin Orthop Trauma"},{"key":"11362_CR36","doi-asserted-by":"publisher","first-page":"915277","DOI":"10.3389\/fimmu.2022.915277","volume":"13","author":"BWM de Wildt","year":"2022","unstructured":"de Wildt BWM, Ito K, Hofmann S (2022) Human platelet lysate as alternative of fetal bovine serum for enhanced human in vitro bone resorption and remodeling. Front Immunol 13:915277. https:\/\/doi.org\/10.3389\/fimmu.2022.915277","journal-title":"Front Immunol"},{"issue":"52","key":"11362_CR37","doi-asserted-by":"publisher","first-page":"43862","DOI":"10.1074\/jbc.M112.407650","volume":"287","author":"EM Lewis","year":"2012","unstructured":"Lewis EM et al (2012) The enzymatic activity of apoptosis-inducing factor supports energy metabolism benefiting the growth and invasiveness of advanced prostate cancer cells. J Biol Chem 287(52):43862\u201375. https:\/\/doi.org\/10.1074\/jbc.M112.407650","journal-title":"J Biol Chem"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11362-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-11362-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11362-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T13:43:51Z","timestamp":1766065431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-11362-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11362"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-11362-w","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant or non-financial interest do disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"209"}}